Predictors of EGFR-mutant primary lung adenocarcinoma.

L Lauren Kriger Groner (University of Miami, Miami, FL) E Eunji Choi L Luchang Cui (Weill Cornell Medicine, New York, NY) J Jonathan Villena-Vargas (Weill Cornell Medicine, New York, NY) N Nasser K. Altorki (Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY) V Vivek Mittal (Weill Cornell Medicine, New York, NY) T Timothy McGraw (Weill Cornell Medicine, New York, NY) Y Yiwey Shieh V Valentina Marulanda Corzo (Molecular Imaging & Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY) L Laura C. Pinheiro (Weill Cornell Medicine, New York, NY)

Abstract

10591 Background: The proportion of lung cancer cases in individuals who have never smoked (INS) is increasing. Most of these cases are adenocarcinoma (AC) harboring Epidermal Growth Factor Receptor (EGFR) mutations. As predictors of AC and mutational status (EGFR positive [EGFRp] vs EGFR negative [EGFRn]) are incompletely elucidated, we sought to identify demographic, clinical, and imaging predictors of EGFRp AC. Methods: Data were obtained from Weill Cornell’s Lung Cancer Database, integrating EGFR mutation status derived from genomic testing, validated natural language processing of unstructured clinical data, and individual and area-level predictors from a large New York City health system. We included patients with early stage, surgically resected primary lung AC, allowing for uniform, robust pathologic and genomic characterization. Lesions were identified on computed tomography (CT) prior to diagnosis The primary outcome was EGFR positivity. LASSO-penalized logistic regression with 10-fold cross-validation was used to identify key predictors in high-dimensional, correlated data. Model performance was evaluated using cross-validated AUC and classification accuracy. Results: Among 1145 adults with primary lung AC (312 subsolid nodules [SSNs] and 833 solid nodules; mean age 69.9 [SD, 9.6]), 58.1% were female and 75.4% had a history of smoking. EGFRp ACs (vs EGFRn) were more likely to present as SSNs (39.3% vs 21.7%, p<0.001) and occur in women (63.6% vs 55.7%, p=0.013), Asian patients (32.7% vs 8.4%, p<0.001), and INS (44.9% vs 15.3%, p<0.001). Those with EGFRp AC were less likely to meet USPSTF lung cancer screening (LCS) criteria (12.5% vs 36.0%, p<0.001) and had lower prevalence of chronic obstructive pulmonary disease, other pulmonary disease, and weight loss at presentation; p<0.05. LASSO-selected predictors of EGFR positivity included SSN density and >1 SSN on CT, former smoking status, family history of LC, and higher exposure to ambient air pollutants (PM2.5, NO2, O3). The model demonstrated good discrimination (AUC 0.77, 0.77-0.78). In the SSN subgroup, new LASSO-selected features positively associated with EGFR positivity included right middle lobe location and lobulated margins on CT and SO2 exposure. Cystic morphology, reticulation, and a new or growing solid component on CT were inversely associated with EGFR positivity. Conclusions: In a robust genomically linked and clinically, radiologically, and environmentally enriched dataset, we identified distinct demographic characteristics (female sex, Asian race, family history of LC), CT features (SSN density, multiplicity, lobulated margins), and environmental exposures (PM2.5, NO2, O3, SO2) that may predict EGFR positivity. Moreover, three-fold fewer adults with EGFRp AC met USPSTF LCS criteria. These findings support integrating imaging and non-tobacco risk factors to inform lung AC risk stratification, genomic testing, and more inclusive screening strategies.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 10591-10591
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (10)

L

Lauren Kriger Groner

University of Miami, Miami, FL

E

Eunji Choi

L

Luchang Cui

Weill Cornell Medicine, New York, NY

J

Jonathan Villena-Vargas

Weill Cornell Medicine, New York, NY

N

Nasser K. Altorki

Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY

V

Vivek Mittal

Weill Cornell Medicine, New York, NY

T

Timothy McGraw

Weill Cornell Medicine, New York, NY

Y

Yiwey Shieh

V

Valentina Marulanda Corzo

Molecular Imaging & Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY

L

Laura C. Pinheiro

Weill Cornell Medicine, New York, NY